Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 3/2020

01-03-2020 | Letter to the Editor

Reply to Letter to the editor regarding “The ZJU index is a powerful index for identifying NAFLD in the general Chinese population”

Author: Linman Li

Published in: Acta Diabetologica | Issue 3/2020

Login to get access

Excerpt

Dear Dr. Fu, …
Literature
1.
Li L, You W, Ren W (2017) The ZJU index is a powerful index for identifying NAFLD in the general Chinese population. Acta Diabetol 54(10):905–911CrossRef
2.
Petta S, Amato M, Cabibi D et al (2010) Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology 52:1543–1552CrossRef
3.
Amato MC, Giordano C, Galia M et al (2010) Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 33:920–922CrossRef
4.
Wang J, Xu C, Xun Y et al (2015) ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. Sci Rep 5:16494CrossRef
5.
Wang J, Ma L, Chen S et al (2018) Risk for the development of non-alcoholic fatty liver disease: a prospective study. J Gastroenterol Hepatol 33(8):1518–1523CrossRef
Metadata
Title
Reply to Letter to the editor regarding “The ZJU index is a powerful index for identifying NAFLD in the general Chinese population”
Author
Linman Li
Publication date
01-03-2020
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 3/2020
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-019-01429-z

Other articles of this Issue 3/2020

Acta Diabetologica 3/2020 Go to the issue

Original Article

Bariatric surgery, compared to medical treatment, reduces morbidity at all ages but does not reduce mortality in patients aged < 43 years, especially if diabetes mellitus is present: a post hoc analysis of two retrospective cohort studies

Short Communication

Interleukin-15 and irisin serum concentrations are not related to cardiometabolic risk factors in patients with type 2 diabetes from Korea and Germany

Original Article

Circulating miR-103 family as potential biomarkers for type 2 diabetes through targeting CAV-1 and SFRP4

Original Article

Saxagliptin attenuates glomerular podocyte injury by increasing the expression of renal nephrin and podocin in type 2 diabetic rats

Original Article

Changes in innate and adaptive immunity over the first year after the onset of type 1 diabetes

Original Article

Trend 2010–2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits